



SPAFID  
CONNECT

Informazione Regolamentata n. 0472-2-2022	Data/Ora Ricezione 18 Gennaio 2022 10:22:49	Euronext Star Milan
---	---	---------------------

Societa' : BB BIOTECH  
Identificativo : 156388  
Informazione  
Regolamentata  
Nome utilizzatore : BIOTECHNSS01 - Alderuccio  
Tipologia : REGEM  
Data/Ora Ricezione : 18 Gennaio 2022 10:22:49  
Data/Ora Inizio : 18 Gennaio 2022 10:22:50  
Diffusione presunta  
Oggetto : Corporate events calendar 2022

*Testo del comunicato*

Vedi allegato.

Press Release, January 18, 2022

## Corporate events calendar – 2022

21/01/2022	Portfolio as of December 31, 2021
18/02/2022	Annual Report 2021
17/03/2022	Annual General Meeting <i>Park Casino, Steigstrasse 26, 8200 Schaffhausen - h. 3 pm</i>
22/04/2022	Interim Report as of March 31, 2022
22/07/2022	Interim Report as of June 30, 2022
21/10/2022	Interim Report as of September 30, 2022

The dates of the meetings with the financial community will be made public later on.

### For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch  
[www.bbbiotech.com](http://www.bbbiotech.com)

**[www.bbbiotech.com](http://www.bbbiotech.com)**

### Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.5 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-2

Numero di Pagine: 3